Recursion Pharmaceuticals, Inc. RXRX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s enterprise value?
- Recursion Pharmaceuticals, Inc. (RXRX) reported enterprise value of $1.04B in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s enterprise value changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s enterprise value decreased by 39.8% year-over-year, from $1.73B to $1.04B.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s enterprise value?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s enterprise value has grown at a -13.9% compound annual growth rate (CAGR), from $2.68B to $1.47B.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.